Dopamine receptor antagonists

Details Dopamine receptor antagonists Dopamine receptor antagonists

1998-10-02

2000-08-22

Gerstl, Robert

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

5462691, C07D41304, A61K 31454

Patent

active

06107313&

ABSTRACT:
This invention provides a novel class of oxadiazolyl piperidines which exhibit a high binding affinity for dopamine ligands. The compounds of the invention display selectivity for the dopamine D.sub.4 receptor over the dopamine D.sub.2 receptor. Preferably, these compounds act as dopamine antagonists, which are useful in the treatment of psychotic disorders.

REFERENCES:
patent: 5262427 (1993-11-01), Nilson
patent: 5559128 (1996-09-01), Chakravarty et al.
patent: 5686463 (1997-11-01), Baker
patent: 5854261 (1998-12-01), Bosmans
Boyfield et al., "Design and Synthesis of 2-Naphthoate Esters as Selective Dopamine D.sub.4 Antagonist", J. Med. Chem. 39:1946-1948 (1996).
Kulagowski et al., "Dopamine D4 Receptor Antagonist", Current Phamaceutical Design, 3:355-366 (1997).
Lahti et al., "Dopamine D.sub.4 versus D.sub.2 receptor selectivity of dopamine receptor antagonist: possible therapeutic implications", European Journal of Pharmacology, 236:483-486 (1983).
Liegeois et al., "Dopamine D.sub.4 Receptors: A New Opportunity for Research on Schizophrenia", Current Medicianal Chemistry, 5:77-100 (1998).
Rowley et al., "4-Heterocyclylpiperidines as Selective High-Affinity Ligands at the Human Dopamine D4 Receptor", J. Med. Chem., 40:2374-2385 (1997).
Rowley et al., "5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: A Potent, Selective Antagonist at Human Cloned Dopamine D4 Receptors", 39:1943-1945 (1996).
Seeman et al., "Atypical Neuroleptics Have Low Affinity for Dopamine D.sub.2 Receptors or Are Selective for D.sub.4 Receptors", Neuropsychopharm, 16:2, 93-100 (1997).
Shaikh et al., "Dopamine D.sub.4 Receptors, Potential Therapeutic Implications in the Treatment of Schizophrenia", CNS Drugs, 8:1-11 (1997).
Andersen, et al., "Oxadiazoles as Bioisosteric Transformations of Carboxylic Functionalities. II", J. Med. Chem., 31:417-425 (1996).
Gupta, et al., "Quantitative Structure-Activity Relationship Studies on Some Nonbenzodiazepine Series of Compounds Acting at the Benzodiazepine Receptor", Bioorganic & Medicinal Chemical Chemistry, 6:2213-2218 (1998).
Street, et al., Synthesis and Biological Activity of 1,2,4-Oxadiazole Derivatives: Highly Potent and Efficacious Agonists for Cortical Muscarinic Receptors, J. Med. Chem., 33:10, 2690-2697 (1990).

Affiliated with

Also associated with

Rating

Dopamine receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dopamine receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dopamine receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-581454